Joshua Phillips

Joshua Phillips has held various positions in the medical and healthcare industry since 2007. Joshua began their career as a Managing General Partner at CHV and has since served as a Director at Epitel (2022), Eyecool Therapeutics (2021), Brixton Biosciences, Inc. (2019), Conformal Medical, Inc. (2018), Cruzar Medsystems Inc (2013), Saphena Medical, Inc. (2013), Sera Prognostics (2011), Pavilion Medical Innovations, LLC (2009), and SevenOaks Biosystems (2014).

Joshua Phillips attended Harvard Business School from 1996 to 1997, where they earned their MBA in Business. Prior to that, they attended Vanderbilt University from 1984 to 1988, where they earned their BE in Electrical Engineering and Mathematics.